1eby
From Proteopedia
(Difference between revisions)
Line 20: | Line 20: | ||
==About this Structure== | ==About this Structure== | ||
- | 1EBY is a | + | 1EBY is a 2 chains structure of sequences from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1EBY OCA]. |
==Reference== | ==Reference== | ||
- | + | <ref group="xtra">PMID:12694187</ref><ref group="xtra">PMID:15560801</ref><references group="xtra"/> | |
- | + | ||
- | + | ||
[[Category: HIV-1 retropepsin]] | [[Category: HIV-1 retropepsin]] | ||
[[Category: Human immunodeficiency virus 1]] | [[Category: Human immunodeficiency virus 1]] | ||
- | [[Category: Single protein]] | ||
[[Category: Unge, T.]] | [[Category: Unge, T.]] | ||
[[Category: Dimer]] | [[Category: Dimer]] | ||
[[Category: Protein-inhibitor complex]] | [[Category: Protein-inhibitor complex]] | ||
- | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Feb 17 06:45:46 2009'' |
Revision as of 04:45, 17 February 2009
HIV-1 protease in complex with the inhibitor BEA369
Template:ABSTRACT PUBMED 12694187
About this Structure
1EBY is a 2 chains structure of sequences from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
Reference
- Andersson HO, Fridborg K, Lowgren S, Alterman M, Muhlman A, Bjorsne M, Garg N, Kvarnstrom I, Schaal W, Classon B, Karlen A, Danielsson UH, Ahlsen G, Nillroth U, Vrang L, Oberg B, Samuelsson B, Hallberg A, Unge T. Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors. Eur J Biochem. 2003 Apr;270(8):1746-58. PMID:12694187
- Lindberg J, Pyring D, Lowgren S, Rosenquist A, Zuccarello G, Kvarnstrom I, Zhang H, Vrang L, Classon B, Hallberg A, Samuelsson B, Unge T. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy. Eur J Biochem. 2004 Nov;271(22):4594-602. PMID:15560801 doi:10.1111/j.1432-1033.2004.04431.x
Page seeded by OCA on Tue Feb 17 06:45:46 2009